Lessons from PROMINENT and prospects for pemafibrate

The neutral result of the PROMINENT trial has led to questions about the future for pemafibrate. This commentary discusses possible reasons for the lack of benefit observed in the trial. There were, however, indicators suggesting therapeutic potential in microvascular ischaemic complications associa...

Full description

Saved in:
Bibliographic Details
Published inCardiovascular diabetology Vol. 23; no. 1; pp. 279 - 8
Main Authors Fruchart, Jean-Charles, Fruchart-Najib, Jamila, Yamashita, Shizuya, Libby, Peter, Yokote, Koutaro, Kodama, Tatsuhiko, Tomita, Yohei, Ridker, Paul M, Hermans, Michel P, Zambon, Alberto
Format Journal Article
LanguageEnglish
Published England BioMed Central 29.07.2024
BMC
Subjects
Animals
Benzoxazoles - adverse effects
Benzoxazoles - therapeutic use
Butyrates - adverse effects
Butyrates - therapeutic use
Cardiovascular disease
Cholesterol
Comment
Creatinine
Diabetes
Diabetes mellitus
Diabetic retinopathy
Fatty liver
Gangrene
High density lipoprotein
Humans
Hypolipidemic Agents - adverse effects
Hypolipidemic Agents - therapeutic use
Ischemia
Ischemia - drug therapy
Ischemia - physiopathology
Lipids
Liver diseases
Metabolic disorders
Microvasculature
Non-alcoholic Fatty Liver Disease - drug therapy
Patients
Pemafibrate
Peripheral Arterial Disease - drug therapy
Peripheral artery disease
PROMINENT trial
Pulmonary embolisms
Risk Factors
Statins
Treatment Outcome
Type 2 diabetes mellitus
Vascular diseases
Peripheral artery disease
Diabetic retinopathy
PROMINENT trial
Type 2 diabetes mellitus
Pemafibrate
Online AccessGet full text

Cover

More Information
Summary:The neutral result of the PROMINENT trial has led to questions about the future for pemafibrate. This commentary discusses possible reasons for the lack of benefit observed in the trial. There were, however, indicators suggesting therapeutic potential in microvascular ischaemic complications associated with peripheral artery disease, with subsequent analysis showing reduction in the incidence of lower extremity ischaemic ulceration or gangrene. Reassurance about the safety of pemafibrate, together with emerging data from PROMINENT and experimental studies, also suggest benefit with pemafibrate in non-alcoholic fatty liver disease (alternatively referred to as metabolic dysfunction-associated steatotic liver disease) and microangiopathy associated with diabetes, which merit further study.
Bibliography:content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ISSN:1475-2840
1475-2840
DOI:10.1186/s12933-024-02305-z